Status:
COMPLETED
Repetitive Assessement of PRECISE-DAPT Score
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Cardiovascular Diseases
Interventional Cardiology
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients treated with percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). Preliminary assessment of the PRECISE-DAPT score is mandatory in order to assess the risk of bl...
Detailed Description
The RE-SCORE trial is a multicenter study aimed at comparing usual care of patients treated with PCI with a novel strategy of change of therapy during follow-up on the base of the Delta PRECISE-DAPT s...
Eligibility Criteria
Inclusion
- Consecutive patients undergoing percutaneous coronary intervention
- Indication to dual antiplatelet therapy for at least 3 months
Exclusion
- \- Contraindications to dual antiplatelet therapy lasting more than 3 months
Key Trial Info
Start Date :
June 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03848572
Start Date
June 1 2017
End Date
December 31 2019
Last Update
March 30 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
San Raffaele Pisana
Rome, Italy, 00100
2
Sapienza University
Rome, Italy, 00161